EGFR and bone metastasis: A very recent real-world study comparing the efficacies of different EGFR-TKIs showed that osimertinib, a third-generation EGFR-TKI, was not superior over other TKIs in patients with liver metastasis, while it provided significant clinical benefits in patients with brain or bone metastasis [35].